184 related articles for article (PubMed ID: 14616939)
1. Clinical experience with trastuzumab (herceptin).
Vogel CL; Franco SX
Breast J; 2003; 9(6):452-62. PubMed ID: 14616939
[TBL] [Abstract][Full Text] [Related]
2. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Slamon D; Pegram M
Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
Burris HA
Semin Oncol; 2001 Feb; 28(1 Suppl 3):38-44. PubMed ID: 11301373
[TBL] [Abstract][Full Text] [Related]
4. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
[TBL] [Abstract][Full Text] [Related]
5. Trials of new combinations of Herceptin in metastatic breast cancer.
Thomssen C
Anticancer Drugs; 2001 Dec; 12 Suppl 4():S19-25. PubMed ID: 11989523
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab/chemotherapy combinations in metastatic breast cancer.
Ligibel JA; Winer EP
Semin Oncol; 2002 Jun; 29(3 Suppl 11):38-43. PubMed ID: 12138396
[TBL] [Abstract][Full Text] [Related]
7. Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
Crown J; Pegram M
Breast Cancer Res Treat; 2003; 79 Suppl 1():S11-8. PubMed ID: 12868801
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-based combination therapy for breast cancer.
Montemurro F; Valabrega G; Aglietta M
Expert Opin Pharmacother; 2004 Jan; 5(1):81-96. PubMed ID: 14680438
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Bullock K; Blackwell K
Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
[TBL] [Abstract][Full Text] [Related]
10. New combinations with Herceptin in metastatic breast cancer.
Winer EP; Burstein HJ
Oncology; 2001; 61 Suppl 2():50-7. PubMed ID: 11694788
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
12. New developments in chemotherapy of advanced breast cancer.
Lebwohl DE; Canetta R
Ann Oncol; 1999; 10 Suppl 6():139-46. PubMed ID: 10676565
[TBL] [Abstract][Full Text] [Related]
13. Ongoing and planned adjuvant trials with trastuzumab.
Perez EA; Hortobagyi GN
Semin Oncol; 2000 Dec; 27(6 Suppl 11):26-32; discussion 92-100. PubMed ID: 11236024
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of chemotherapy by anti-HER.
Kataoka A; Ishida M; Murakami S; Ohno S
Breast Cancer; 2004; 11(2):105-15. PubMed ID: 15550854
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel/trastuzumab combination therapy for the treatment of breast cancer.
Nabholtz JM; Gligorov J
Expert Opin Pharmacother; 2005 Aug; 6(9):1555-64. PubMed ID: 16086643
[TBL] [Abstract][Full Text] [Related]
16. A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer.
Chan A
Ann Oncol; 2007 Jul; 18(7):1152-8. PubMed ID: 17264064
[TBL] [Abstract][Full Text] [Related]
17. The platinum agents: a role in breast cancer treatment?
Crown JP
Semin Oncol; 2001 Feb; 28(1 Suppl 3):28-37. PubMed ID: 11301372
[TBL] [Abstract][Full Text] [Related]
18. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials.
Hortobagyi GN; Perez EA
Semin Oncol; 2001 Oct; 28(5 Suppl 16):41-6. PubMed ID: 11706395
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab-based combinations in metastatic breast cancer: how to make a choice.
Jahanzeb M
Clin Breast Cancer; 2003 Apr; 4(1):28-38. PubMed ID: 12744756
[TBL] [Abstract][Full Text] [Related]
20. Current and planned clinical trials with trastuzumab (Herceptin).
Baselga J
Semin Oncol; 2000 Oct; 27(5 Suppl 9):27-32. PubMed ID: 11049054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]